The U.S. Preventive Services Task Force has released a statement recommending that physicians talk with women at high risk of developing breast cancer about drugs that might reduce their risk. Tamoxifen or raloxifene interfere with the effects of estrogen in breast tissue, but they are associated with side effects including blood clot risk.

Full Story:

Related Summaries